OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone1-855-961-9420
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.27 million
Profitability
Miscellaneous
Employees615
Next Earnings Date1/27/2020 (Estimated)
OptionableNot Optionable
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc (NASDAQ:OGI) posted its quarterly earnings results on Monday, July, 15th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.02 by $0.09. The company had revenue of $30.36 million for the quarter, compared to analysts' expectations of $30.81 million. OrganiGram had a negative return on equity of 7.21% and a negative net margin of 11.16%. The company's revenue was up 782.6% on a year-over-year basis. View OrganiGram's Earnings History.
When is OrganiGram's next earnings date?
What price target have analysts set for OGI?
9 Wall Street analysts have issued 1-year price targets for OrganiGram's stock. Their forecasts range from $8.20 to $17.10. On average, they anticipate OrganiGram's stock price to reach $10.96 in the next year. This suggests a possible upside of 324.8% from the stock's current price. View Analyst Price Targets for OrganiGram.
What is the consensus analysts' recommendation for OrganiGram?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OrganiGram.
Has OrganiGram been receiving favorable news coverage?
News coverage about OGI stock has trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. OrganiGram earned a daily sentiment score of 2.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for OrganiGram.
Are investors shorting OrganiGram?
OrganiGram saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,280,000 shares, an increase of 46.1% from the September 15th total of 2,930,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.9% of the company's stock are short sold. View OrganiGram's Current Options Chain.
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include Epizyme (EPZM), Akcea Therapeutics (AKCA), Zymeworks (ZYME), Axsome Therapeutics (AXSM), Alder Biopharmaceuticals (ALDR), Corcept Therapeutics (CORT), Karuna Therapeutics (KRTX), Constellation Pharmaceuticals (CNST), Myovant Sciences (MYOV), Nabriva Therapeutics (NBRV), Athenex (ATNX), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB) and Arvinas (ARVN).
What other stocks do shareholders of OrganiGram own?
Who are OrganiGram's key executives?
OrganiGram's management team includes the folowing people:
- Mr. Greg Engel, CEO & Director (Age 54)
- Mr. Paolo De Luca C.A., C.F.A, Chief Financial Officer (Age 46)
- Mr. Jeff Purcell, VP - Operations
- Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
- Mr. Peter R. Hanson, Director of Fin.
Who are OrganiGram's major shareholders?
OrganiGram's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ancora Advisors LLC (0.21%), Commonwealth Equity Services LLC (0.06%), Sigma Planning Corp (0.04%), Penserra Capital Management LLC (0.04%), Cambridge Investment Research Advisors Inc. (0.02%) and Traynor Capital Management Inc. (0.02%).
Which major investors are selling OrganiGram stock?
OGI stock was sold by a variety of institutional investors in the last quarter, including Ancora Advisors LLC and Virtu Financial LLC.
Which major investors are buying OrganiGram stock?
OGI stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Penserra Capital Management LLC, Cambridge Investment Research Advisors Inc., Signition LP, Millennium Management LLC, Archford Capital Strategies LLC, Wedbush Securities Inc. and Commonwealth Equity Services LLC.
How do I buy shares of OrganiGram?
Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OrganiGram's stock price today?
One share of OGI stock can currently be purchased for approximately $2.58.
How big of a company is OrganiGram?
OrganiGram has a market capitalization of $402.94 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.View Additional Information About OrganiGram.
What is OrganiGram's official website?
How can I contact OrganiGram?
OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.
MarketBeat Community Rating for OrganiGram (NASDAQ OGI)
MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote "Outperform" if you believe OGI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days.
